Overview

Efficacy and Safety of ATL-962 in Obese Diabetics

Status:
Completed

Trial end date:
2005-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients

Phase:

Phase 2

Details

Lead Sponsor:

Alizyme

Treatments:

Orlistat